| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
LpPLA2 (lipoprotein-associated phospholipase A2). 1-Linoleoyl Glycerol is a LpPLA2 inhibitor and also inhibits PAF-AH with an IC₅0 of 45 uM. It is a 1-acyl-sn-glycerol, the S-enantiomer of 1-monolinoleic acid glyceride. The compound has potential applications in cholesterol lowering and antiatherogenic activity.
|
|---|---|
| ln Vitro |
1-Linoleoyl Glycerol inhibits LpPLA2 and PAF-AH with an IC₅0 of 45 uM. It acts as a precursor for synthesizing various functional lipids, such as phospholipids. The compound has potential applications in cholesterol lowering and antiatherogenic activity and serves as a biomarker of metabolic responses.
|
| ln Vivo |
In vivo, 1-Linoleoyl Glycerol would be expected to demonstrate lipid-modulating effects through LpPLA2 inhibition. The compound has potential applications in cholesterol lowering and antiatherogenic activity. Efficacy would be assessed in models of atherosclerosis, dyslipidemia, and metabolic disorders.
|
| Enzyme Assay |
LpPLA2 or PAF-AH enzymatic activity is measured using a fluorogenic or radiometric substrate assay. The enzyme is incubated with a phospholipid substrate and serial dilutions of test compound. Product formation is quantified, and IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
Cells (e.g., macrophages, endothelial cells) are treated with 1-Linoleoyl Glycerol at various concentrations. Lipid metabolism and inflammatory cytokine production are assessed. Cell viability is evaluated using MTT or CellTiter-Glo assays. The compound's effects on phospholipid synthesis and metabolism are studied using lipidomics approaches.
|
| Animal Protocol |
Animal models of atherosclerosis, dyslipidemia, or metabolic disorders are administered 1-Linoleoyl Glycerol via appropriate routes. Lipid profiles in serum and tissues are measured. Inflammatory markers and atherosclerotic lesion formation are assessed. Efficacy is determined by improvement in lipid parameters and reduction in disease burden.
|
| ADME/Pharmacokinetics |
1-Linoleoyl Glycerol has a molecular weight of 354.52 g/mol and formula C21H3₈O4. As a fatty acid glycerol, it is lipophilic and formulated in suitable vehicles for in vivo or in vitro use. Standard PK parameters would be determined in rodent studies.
|
| Toxicity/Toxicokinetics |
Toxicology data for 1-Linoleoyl Glycerol are not publicly available. Standard preclinical safety assessment would include cytotoxicity screening and repeat-dose toxicology studies in rodents. As a lipid compound, potential effects on lipid metabolism and liver function would be evaluated.
|
| References | |
| Additional Infomation |
1-Linoleoyl-sn-glycerol is a 1-acyl-sn-glycerol, the S-enantiomer of 1-monolinoleic acid glyceride. It is both 1-monolinoleic acid glyceride and 1-acyl-sn-glycerol. It is the enantiomer of 3-linoleoyl-sn-glycerol. α-Glyceryl linoleate has been reported in Streptomyces piomogenus, and relevant data are available. See also: corn glyceride (note moved here); glyceryl linoleate (note moved here).
1-Linoleoyl Glycerol is a research compound for studying lipid metabolism and inflammation. It is not clinically approved. The compound is a fatty acid glycerol, a LpPLA2 inhibitor, and a precursor for synthesizing phospholipids. It has potential applications in cholesterol lowering and antiatherogenic activity and serves as a biomarker of metabolic responses to hepatotoxicants and carcinogens. |
| Molecular Formula |
C21H38O4
|
|---|---|
| Molecular Weight |
354.52402
|
| Exact Mass |
354.277
|
| CAS # |
2277-28-3
|
| PubChem CID |
6436630
|
| Appearance |
Light yellow to yellow ointment
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
485.0±40.0 °C at 760 mmHg
|
| Flash Point |
157.0±20.8 °C
|
| Vapour Pressure |
0.0±2.8 mmHg at 25°C
|
| Index of Refraction |
1.489
|
| LogP |
6.19
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
25
|
| Complexity |
350
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCC/C=C\C/C=C\CCCCCCCC(OCC(O)CO)=O
|
| InChi Key |
WECGLUPZRHILCT-GSNKCQISSA-N
|
| InChi Code |
InChI=1S/C21H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-21(24)25-19-20(23)18-22/h6-7,9-10,20,22-23H,2-5,8,11-19H2,1H3/b7-6-,10-9-/t20-/m0/s1
|
| Chemical Name |
[(2S)-2,3-dihydroxypropyl] (9Z,12Z)-octadeca-9,12-dienoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~282.07 mM)
Ethanol : ~100 mg/mL (~282.07 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8207 mL | 14.1036 mL | 28.2072 mL | |
| 5 mM | 0.5641 mL | 2.8207 mL | 5.6414 mL | |
| 10 mM | 0.2821 mL | 1.4104 mL | 2.8207 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
